Clinical Trials Logo

Renal Cell Cancer clinical trials

View clinical trials related to Renal Cell Cancer.

Filter by:

NCT ID: NCT06362369 Recruiting - Colorectal Cancer Clinical Trials

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Start date: May 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b

NCT ID: NCT05363072 Completed - Clinical trials for Renal Cell Carcinoma

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Start date: June 1, 2022
Phase:
Study type: Observational

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

NCT ID: NCT05329532 Recruiting - Clinical trials for Triple Negative Breast Cancer

Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer

ModiFY
Start date: April 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1/Modi-1v vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.

NCT ID: NCT05263609 Withdrawn - Renal Cell Cancer Clinical Trials

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

Start date: June 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research is to test the response of study participants' tumor to pembrolizumab alone, and in combination with axitinib, and to see what effects (good and bad) these drugs have on patients with advanced kidney cancer.

NCT ID: NCT05061537 Terminated - Colorectal Cancer Clinical Trials

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Start date: October 20, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

NCT ID: NCT04969315 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors

Start date: June 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of orally administered TT-10 in subjects with advanced selected solid tumors. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of TT-10.

NCT ID: NCT04714983 Suspended - Breast Cancer Clinical Trials

DNX-2440 for Resectable Colorectal Liver Metastasis

Start date: February 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.

NCT ID: NCT04714697 Not yet recruiting - Renal Cell Cancer Clinical Trials

Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This study is a phase 2, multicenter, interventional for cohort 1 & 2, non-interventional for cohort 3, open-label trial of cabozantinib, with ORR as the primary efficacy endpoint. In total, 201 eligible subjects will enroll from 5 sites in Korea. The intervention for this cohort 1&2 is only IMP, Cabometyx provided by Ipsen (off-label). Also, cohort 3 is just RWD without IMP (on-label)

NCT ID: NCT04625556 Recruiting - Prostate Cancer Clinical Trials

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Start date: December 19, 2022
Phase:
Study type: Observational [Patient Registry]

Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of technologies, studies have found that microbiome not only affects human physiological functions, such as metabolism, immunity, and haematopoiesis, but also plays a significant role in the development and progression of malignancies. However, the investigation of microbiome in urological malignances have been limited and few studies have been reported. Therefore, the investigator tried to evaluate the usefulness of microbiome in detection and monitoring of urological malignancies in Korean population. This study aims to use microbiome in tissue, plasma, stool and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for microbiome of urological malignancies in Korean population.

NCT ID: NCT04620603 Recruiting - Renal Cell Cancer Clinical Trials

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Start date: May 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.